Bank of America now spends over $250 million a year on GLP-1 weight-loss drugs for its staff, up from zero five years ago.

Multiply that across corporate America and you see the demand curve behind $LLY and $NVO.

Eli Lilly's revenue is projected to grow 72% to $112B by 2028. It scores 93/100 on our Growth rating, the only US non-AI mega cap above 90.